Rapport Therapeutics Inc
RAPPHealthcare|Biotechnology|USA
$41.79
-0.25 (-0.60%)
Tangible Book
$9.86
Upcoming Data Readouts (4)
Sep 2026
Est. completion
P2Bipolar 1 Disorder
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder
NCT07046494n=250
Feb 2028
Est. completion
P2Focal Epilepsy
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
NCT07219407n=30
Jul 2029
Est. completion
P3Focal Seizure
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures
NCT07594119n=312
Jul 2029
Est. completion
P3Focal Seizure
Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1
NCT07563881n=333